Halemah Alsaeed

Ms. Halemah Alsaeed

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2025 in The Journal of Immunology
Verified
Journal Article
Open access
FAFatema Al-Rashed
Fatema Al-Rashed
HAHalemah Alsaeed
Halemah Alsaeed
NANadeem Akhter
Nadeem Akhter
HAHaya Alabduljader
Haya Alabduljader
FAFahd Al-Mulla
Fahd Al-Mulla
Rasheed AhmadRasheed Ahmad
Rasheed Ahmad
The relationship between sleep deprivation, obesity, and systemic inflammation is a critical area of investigation due to its significant impact on health. While it is established that poor sleep adversely affects obesity and metabolic syndromes, the specific mechanisms, particularly subclinical inflammation independent of obesity, remain unclear. This study investigates how sleep quality influences monocyte subclass distribution and its association with systemic inflammation across a spectrum of body mass index categories. In our cohort study, 237 healthy participants were categorized by body mass index. Participants' dietary intake, physical activity, and sleep patterns were objectively tracked through wearable ActiGraph GT3X accelerometer. The data showed that obese individuals had significantly lower sleep quality and higher chronic low-grade inflammation. Nonclassical monocytes increased significantly in obesity, correlating with reduced sleep quality and elevated proinflammatory cytokines. Although body mass index emerged as a significant factor in driving inflammation, mediation analyses further defined that sleep disruption independently contributes to inflammation, regardless of obesity status. Controlled sleep deprivation experiments confirmed these findings, demonstrating reversible increases in nonclassical monocytes expression. This study highlights the importance of sleep quality in regulating immune responses and inflammation in obesity, suggesting that improving sleep quality could reduce inflammation and improve health outcomes.

1 January 2025 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
HAHaya AlAbduljader
Haya AlAbduljader
HAHalemah Alsaeed
Halemah Alsaeed
AAAmenah Alrabeea
Amenah Alrabeea
ASAmeenah Sulaiman
Ameenah Sulaiman
MHMohammed Haider
Mohammed Haider
FAFatema Al-Rashed
Fatema Al-Rashed
Metabolic‐endotoxemia, characterized by the translocation of lipopolysaccharide (LPS) from Gram‐negative bacteria into the bloodstream, is a key contributor to chronic low‐grade inflammation associated with obesity and type 2 diabetes. This condition exacerbates metabolic disruptions by activating Toll‐like receptor 4 (TLR4) on macrophages, leading to the release of pro‐inflammatory cytokines and subsequent insulin resistance. Eicosapentaenoic acid (EPA; C20:5 (n‐3)), an omega‐3 polyunsaturated fatty acid, has demonstrated anti‐inflammatory and antioxidative properties, but its precise mechanisms of action in mitigating LPS‐induced stress remain unclear. This study investigates the pathways through which C20:5 (n‐3) alleviates LPS‐induced oxidative stress and inflammation in macrophages. C20:5 (n‐3) pretreatment significantly reduced LPS‐induced inflammatory responses, decreasing IL‐1β and IL‐6 expression and IL‐1β secretion, and lowering the percentage of HLA‐DR + macrophages. C20:5 (n‐3) also attenuated ER stress, evidenced by reduced expression of ATF4, DDIT3, HSPA5/GRP78, BIP, and CHOP at both gene and protein levels. Oxidative stress was mitigated, as shown by decreased HIF1α expression, reduced ROS levels, and preservation of mitochondrial membrane potential. Importantly, C20:5 (n‐3) increased the expression of PPARα and FABP5 while inhibiting NF‐κB activation independently of the TLR4‐IRF5 pathway. The protective effects of C20:5 (n‐3) was abolished by PPARα inhibition with GW9662, indicating that C20:5 (n‐3)’s action is PPARα‐dependent. This study highlights the modulatory role of C20:5 (n‐3) in alleviating LPS‐induced oxidative stress and inflammation in macrophages through activation of the FABP5/PPARα/NF‐κB axis, independently of TLR4‐IRF5 signaling. These findings reveal a novel mechanism for C20:5 (n‐3)’s anti‐inflammatory effects and suggest that targeting the FABP5/PPARα pathway may offer therapeutic potential for treating metabolic disorders associated with chronic inflammation.

6 March 2024 in Cells
Verified
Journal Article
Open access
PDF file
FAFatema Al-Rashed
Fatema Al-Rashed
HAHossein Arefanian
Hossein Arefanian
AMAshraf Al Madhoun
Ashraf Al Madhoun
FBFatemah Bahman
Fatemah Bahman
Sardar SindhuSardar Sindhu
Sardar Sindhu
Rasheed AhmadRasheed Ahmad
Rasheed Ahmad
Non-alcoholic fatty liver disease (NAFLD) is manifested by hepatic steatosis, insulin resistance, hepatocyte death, and systemic inflammation. Obesity induces steatosis and chronic inflammation in the liver. However, the precise mechanism underlying hepatic steatosis in the setting of obesity remains unclear. Here, we report studies that address this question. After 14 weeks on a high-fat diet (HFD) with high sucrose, C57BL/6 mice revealed a phenotype of liver steatosis. Transcriptional profiling analysis of the liver tissues was performed using RNA sequencing (RNA-seq). Our RNA-seq data revealed 692 differentially expressed genes involved in processes of lipid metabolism, oxidative stress, immune responses, and cell proliferation. Notably, the gene encoding neutral sphingomyelinase, SMPD3, was predominantly upregulated in the liver tissues of the mice displaying a phenotype of steatosis. Moreover, nSMase2 activity was elevated in these tissues of the liver. Pharmacological and genetic inhibition of nSMase2 prevented intracellular lipid accumulation and TNFα-induced inflammation in in-vitro HepG2-steatosis cellular model. Furthermore, nSMase2 inhibition ameliorates oxidative damage by rescuing PPARα and preventing cell death associated with high glucose/oleic acid-induced fat accumulation in HepG2 cells. Collectively, our findings highlight the prominent role of nSMase2 in hepatic steatosis, which could serve as a potential therapeutic target for NAFLD and other hepatic steatosis-linked disorders.

6 February 2026 in Cells
Verified
Journal Article
Open access
PDF file
HAHalemah Alsaeed
Halemah Alsaeed
HAHesah Khaled Almusallam
Hesah Khaled Almusallam
SMShayndel Menezes
Shayndel Menezes
HAHessah Almelaifi
Hessah Almelaifi
HAHussah Alonaizi
Hussah Alonaizi
FAFatema Al-Rashed
Fatema Al-Rashed
Dietary fats are consumed as mixtures, yet it remains unclear whether fatty acid composition, independent of fat content, dictates human macrophage polarization. We compared two defined mixtures containing identical fatty acids (palmitic, oleic, and linoleic acids) in different ratios: a palmitate-enriched mixture (4:3:3) and an unsaturated fat-dominant mixture (2:4:4). In primary human monocyte-derived macrophages, palmitate enrichment increased CD14+CD11b+HLA-DR+ pro-inflammatory polarization, whereas the unsaturated fat-dominant mixture increased CD14+CD11b+CD163+ anti-inflammatory polarization. Mechanistic studies in THP-1-derived macrophages recapitulated these phenotype shifts and identified a reciprocal nuclear-receptor program: palmitate enrichment induced peroxisome proliferator-activated receptor gamma (PPARγ), together with ER-stress mediators EIF2AK3 and DDIT3, while the unsaturated fat-dominant mixture preferentially induced PPARα and IRF4. Pharmacologic modulation demonstrated functional dependence on PPARγ: GW9662 attenuated palmitate-driven M1-like polarization, whereas rosiglitazone disrupted the protective program under unsaturated fat-dominant conditions. These findings show that fatty acid composition, at equivalent total lipid concentration, is a dominant determinant of human macrophage inflammatory fate and highlight PPARγ as a context-dependent lipid sensor.

29 October 2025 in Cells
Verified
Journal Article
Open access
PDF file
HAHossein Arefanian
Hossein Arefanian
FAFatema Al-Rashed
Fatema Al-Rashed
FAFawaz Alzaid
Fawaz Alzaid
FBFatemah Bahman
Fatemah Bahman
NANermeen Abukhalaf
Nermeen Abukhalaf
Ashraf MadhounAshraf Madhoun
Ashraf Madhoun
Diabetes remains a global health challenge, characterized by persistent hyperglycemia and gradual depletion or impairment of pancreatic β-cells. Current treatments focus on managing glycemic control, but do not mitigate β-cell mass. Verapamil, an FDA-approved calcium channel blocker for hypertension, has shown potential therapeutic action towards β-cells in the context of diabetes. In this study, we investigated the cytoprotective and metabolic efficacy of verapamil on mouse-derived MIN6 β-cells under metabolic and diabetogenic stressors like high glucose, toxins, and an inflammatory cytokine cocktail, as well as investigated a zebrafish model. At safe, non-toxic doses, verapamil elevated the levels of cholecystokinin (CCK), an incretin associated with β-cell preservation and enhanced mitochondrial respiration. Notably, pretreatment and co-treatment of verapamil in the presence of stressors offered substantial protection and preserved mitochondrial function, whereas post-treatment effects were moderate and model dependent. In the zebrafish model, verapamil promoted β-cell recovery and regeneration before, during, and after targeted ablation. The drug seemed to work in several ways: inducing proliferation, reducing stress on β cells, boosting their energy production, and activating survival signals. Together, our data aligned with earlier human clinical trials showing that verapamil administration preserved β-cell mass and function in patients with recent-onset type 1 diabetes. The high efficacy, affordability, and broad mechanisms of action make verapamil a desirable therapeutic candidate for diabetes. Nevertheless, further mechanistic studies and long-term clinical trials are warranted to establish its utility in diabetes management.

30 May 2024 in Cells
Verified
Journal Article
Open access
PDF file
HAHossein Arefanian
Hossein Arefanian
Ashraf MadhounAshraf Madhoun
Ashraf Madhoun
FAFatema Al-Rashed
Fatema Al-Rashed
FAFawaz Alzaid
Fawaz Alzaid
FBFatemah Bahman
Fatemah Bahman
FAFahd Al-Mulla
Fahd Al-Mulla
This study unveils verapamil’s compelling cytoprotective and proliferative effects on pancreatic β-cells amidst diabetic stressors, spotlighting its unforeseen role in augmenting cholecystokinin (CCK) expression. Through rigorous investigations employing MIN6 β-cells and zebrafish models under type 1 and type 2 diabetic conditions, we demonstrate verapamil’s capacity to significantly boost β-cell proliferation, enhance glucose-stimulated insulin secretion, and fortify cellular resilience. A pivotal revelation of our research is verapamil’s induction of CCK, a peptide hormone known for its role in nutrient digestion and insulin secretion, which signifies a novel pathway through which verapamil exerts its therapeutic effects. Furthermore, our mechanistic insights reveal that verapamil orchestrates a broad spectrum of gene and protein expressions pivotal for β-cell survival and adaptation to immune-metabolic challenges. In vivo validation in a zebrafish larvae model confirms verapamil’s efficacy in fostering β-cell recovery post-metronidazole infliction. Collectively, our findings advocate for verapamil’s reevaluation as a multifaceted agent in diabetes therapy, highlighting its novel function in CCK upregulation alongside enhancing β-cell proliferation, glucose sensing, and oxidative respiration. This research enriches the therapeutic landscape, proposing verapamil not only as a cytoprotector but also as a promoter of β-cell regeneration, thereby offering fresh avenues for diabetes management strategies aimed at preserving and augmenting β-cell functionality.